Clinical Trials Update: Mar. 12, 2004

HIV Postherpetic Neuralgia Pseudobulbar Affect

(HealthDayNews) -- Here are the latest clinical trials, courtesy of CenterWatch:

HIV

A research study of an investigational medication for the treatment of painful symptoms of HIV-associated neuropathy. Volunteers who have had HIV-associated neuropathy for at least two months, with moderate to severe pain in both feet, do not have significant foot pain due to other causes, and are able to remain on any pain medications being taken for the entire study duration (one year) may be eligible. Research sites located throughout the United States.

More Information

Please see http://www.centerwatch.com/patient/studies/cat417.html.

-----

Postherpetic Neuralgia

A 12-week study of an investigational medication for patients who are experiencing pain after shingles (postherpetic neuralgia). Volunteers who have a diagnosis of postherpetic neuralgia with pain that still persists at least three months after the rash from shingles has healed and do not have significant pain due to other causes may be eligible. Research sites located throughout the United States.

More Information

Please see http://www.centerwatch.com/patient/studies/cat638.html.

-----

Pseudobulbar Affect

A research study of an investigational drug that may assist in the reduction of uncontrolled episodes of laughing and crying for patients suffering from Pseudobulbar Affect. The condition can occur in people who have multiple sclerosis, ALS, stroke, traumatic brain injury, or other diseases involving the brain. Research site located in Albany, NY.

More Information

Please see http://www.centerwatch.com/patient/studies/cat608.html.

-----

Copyright 2004 CenterWatch. All rights reserved.

Consumer News